CA2251194C - Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale - Google Patents

Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale Download PDF

Info

Publication number
CA2251194C
CA2251194C CA002251194A CA2251194A CA2251194C CA 2251194 C CA2251194 C CA 2251194C CA 002251194 A CA002251194 A CA 002251194A CA 2251194 A CA2251194 A CA 2251194A CA 2251194 C CA2251194 C CA 2251194C
Authority
CA
Canada
Prior art keywords
composition
lipid
dry
solid
coqlo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002251194A
Other languages
English (en)
Other versions
CA2251194A1 (fr
Inventor
Shimon Amselem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmos Corp
Original Assignee
Pharmos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL11777396A external-priority patent/IL117773A/xx
Application filed by Pharmos Corp filed Critical Pharmos Corp
Publication of CA2251194A1 publication Critical patent/CA2251194A1/fr
Application granted granted Critical
Publication of CA2251194C publication Critical patent/CA2251194C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

On mélange des substances lipophiles présentant une faible biodisponibilité orale avec au moins une graisse solide et un phospholipide pour obtenir une composition solide à l'état sec appropriée pour être utilisée sous une forme galénique buvable. Ces compositions lipidiques solides sont données à titre d'exemple pour des additifs et compléments alimentaires tels que la coenzyme Q10 et pour des produits pharmaceutiques tels que déxanabinol. Les mélanges lipidiques secs comportant la coenzyme Q10 présentent une meilleure libération du médicament in vitro et une meilleure biodisponibilité orale in vivo comparé à une formulation du commerce CoQ10. Le mélange lipidique sec comprenant déxanabinol présente de manière similaire une bien meilleure biodisponibilité orale comparé aux formulations connues.
CA002251194A 1996-04-02 1997-04-02 Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale Expired - Fee Related CA2251194C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL117773 1996-04-02
IL11777396A IL117773A (en) 1996-04-02 1996-04-02 Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
PCT/US1997/005453 WO1997036577A1 (fr) 1996-04-02 1997-04-02 Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale

Publications (2)

Publication Number Publication Date
CA2251194A1 CA2251194A1 (fr) 1997-10-09
CA2251194C true CA2251194C (fr) 2006-08-01

Family

ID=36764355

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002251194A Expired - Fee Related CA2251194C (fr) 1996-04-02 1997-04-02 Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale

Country Status (1)

Country Link
CA (1) CA2251194C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3036585A1 (fr) * 2016-09-27 2018-04-05 CannTab Therapeutics Limited Formulations de cannabinoides a liberation prolongee

Also Published As

Publication number Publication date
CA2251194A1 (fr) 1997-10-09

Similar Documents

Publication Publication Date Title
AU722217B2 (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
AU730216B2 (en) Solid coprecipitates for enhanced bioavailability of lipophilic substances
US5891469A (en) Solid Coprecipitates for enhanced bioavailability of lipophilic substances
JP2911814B2 (ja) リポソーム性の水中分散する経口投与可能な固体乾燥治療用処方の製造方法
JP2001505928A (ja) シクロスポリン及び陰イオン性界面活性剤を含む固体医薬組成物
US20050244488A1 (en) Methods and formulations for enhansing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
US20120225118A1 (en) Compositions for delivery of insoluble agents
WO1995022982A1 (fr) Composition pulverulente renfermant de la cyclosporine
JP2004518707A (ja) カロテノイドを充填されたリポソーム
US9655849B2 (en) Solid particulate compositions comprising coenzyme Q10
CN105007898A (zh) 难溶性药物的过饱和的稳定纳米颗粒
JPS6230965B2 (fr)
US20130108689A1 (en) Methods and formulations for enhancing the absorption and gastro-intestinal bioavailability of hydrophobic drugs
CA2251194C (fr) Compositions lipidiques solides de composes lipophiles pour ameliorer la biodisponibilite orale
IL126384A (en) Solid lipid compositions of lipophilic compounds for enhanced oral bioavailability
NL2020916B1 (en) Composition comprising dehydrated liposomes with nutritional supplement
GB2260080A (en) Gelled alginate compositions
IL119176A (en) Soluble coprecipitates for enhanced oral bioavailability of lipophilic substances
MXPA99001663A (en) Method for producing dispersible sterol formulations in a

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20120402